<DOC>
	<DOCNO>NCT01435343</DOCNO>
	<brief_summary>Second-line induction therapy fludarabine , idarubicin , cytarabine , Granulocyte colony-stimulating factor ( G-CSF ) plerixafor , patient relapse refractory Acute Myeloblastic Leukemia ( AML ) age 65 younger .</brief_summary>
	<brief_title>Treatment Relapsed Refractory Acute Myeloblastic Leukemia</brief_title>
	<detailed_description>This protocol correspond multicenter , open-label , non-randomized , Phase I-II study design determine safety efficacy combination plerixafor chemotherapy young patient relapse refractory AML . The clinical trial divide pre-treatment treatment period ( induction consolidation cycle ( ) consist two general phase : initial Phase I escalate dos plerixafor give 4 group , 3 patient ; secondary Phase II additional patient group treat maximum tolerate dose ( MTD ) Phase I . In pre-treatment period , patient provide write informed consent screen patient meet inclusion none exclusion criterion eligible treatment . The patient finally include study begin treatment within 7 day sign informed consent document ( ICD ) . The pre-treatment period begin ICD sign enrollment occur patient receives first study drug treatment regimen ( i.e. , Day 1 induction cycle ) . In study , induction cycle consist fludarabine 30 mg/m2/day intravenously day 1 4 , idarubicin 10 mg/m2/day intravenously day 1 3 , cytarabine 2 g/m2/day intravenously day 1 4 , G-CSF 5 μg/kg/day subcutaneously day 1 4 , plerixafor intravenously day 1 4 . The dose plerixafor escalate 4 group three patient follow : 240 μg/kg/day ( 120 μg/kg/12 h ) ; 320 μg/kg/day ( 160 μg/kg/12 h ) ; 400 μg/kg/day ( 200 μg/kg/12 h ) ; 480 μg/kg/day ( 240 μg/kg/12 h ) . If MTD observe first treatment dose plerixafor dose progressively deescalated 160 μg/kg/day ( 80μg/kg/12 h ) first deescalating level 240 μg/kg/day single daily dose second deescalating level twice day ( BID ) dose tolerate . Patient enrollment expand total 55 patient use MTD . If patient achieve CR one induction cycle leave study follow accord routine clinical practice . Patients achieve complete response ( CR ) eligible allogeneic hematopoietic stem cell transplantation ( HSCT ) donor leave trial receive allogeneic HSCT follow accord routine clinical practice . Patients achieve CR eligible allogeneic HSCT donor receive two consolidation cytarabine 3 g/m2/12 hour day 1 , 3 5 along Granulocyte colony-stimulating factor ( GCSF ) 5 μg/kg/day day 1 5 plerixafor dose use induction cycle day 1 , 3 5 , coincide day cytarabine administer . In context protocol , treatment cycle define first day study drug administration regimen ( Day 1 ) include day first day treatment cycle immediately afterwards . The treatment cycle begin Day 28 later Day 85 , count Day 1 treatment cycle immediately . Patients assess three day cycle ( see Appendix A ) . Follow-up , outside protocol routine clinical practice , perform monthly first year least every three month second year ; notwithstanding , visit may frequent discretion site base clinical characteristic . All treatment cycle administer patient hospitalize . Clinical procedure care patient acute leukemia require flexibility . However , deviation study treatment define section must prospectively discussed coordinator .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Diagnosis AML accord WHO criterion Relapsed refractory AML define First relapse standard treatment duration first remission less year Refractoriness induction cycle include cytarabine anthracyclines Nonpromyelocytic leukemia ( absence ( 15 ; 17 ) PMLRARα rearrangement variant ) Peripheral blood blast cell count le 50 x 109/L . Hydroxyurea leukopheresis use low blast count prior begin treatment Age ≤ 65 year ≥ 18 year ECOG performance status 02 Provide sign write informed consent Be able comply study procedure followup examination Be nonfertile agree use birth control study end last treatment visit Adequate renal hepatic function indicate follow : Total bilirubin &lt; 1.5 x Institutional Upper Limit Normal ( ULN ) ; AST ALT &lt; 2.5 xULN ; Serum creatinine &lt; 1.0 mg/dL ; serum creatinine &lt; 1.0 mg/dL , , estimate glomerular filtration rate ( GFR ) must &lt; 60 ml/min/1.73 m2 calculate Modification Diet Renal Disease ( MDRD ) equation Minimal impairment cardiac function measure least 1 follow : Left ventricular ejection fraction ( LVEF ) &gt; 40 % multigated acquisition ( MUGA ) scan radionuclide angiographic scan ; Left ventricular fractional shortening &gt; 22 % echocardiography exam ; Diagnosis acute promyelocytic leukemia ( APL , FrenchAmericanBritish [ FAB ] classification M3 WHO classification APL ( 15 ; 17 ) ( q22 ; q12 ) , ( PML/RARalfa variant ) AML secondary previous treatment myelodysplastic syndrome ( MDS ) Peripheral blood blast cell count ≥ 50 x 109/L . Hydroxyurea leukopheresis use low blast count prior begin treatment Prior investigational treatment within 30 day prior first dose study drug . If investigational treatment receive prior time point , drug related toxicity must recover Grade 1 less prior first dose study drug Prior hematopoietic stem cell transplant ( HSCT ) ( previous autologous hematopoietic stem cell transplant allow ) Investigational agent receive within 5 day prior first dose study drug . If receive investigational agent prior time point , drugrelated toxicity must recover Grade 1 less prior first dose study drug Impaired renal liver function indicate follow : Total bilirubin &gt; 1.5 x upper limit normal ( ULN ) provide attributable AML ; AST ALT &gt; 2.5 xULN provide attributable AML ; Serum creatinine &gt; 1.0 mg/dL provide estimate glomerular filtration rate ( GFR ) ≤ 60 mL/min/1.73 m2 calculate Modification Diet Renal Disease ( MDRD ) equation Impaired cardiac function measure least 1 follow : Left ventricular ejection fraction ( LVEF ) &lt; 40 % multigated acquisition ( MUGA ) scan radionuclide angiographic scan ; Left ventricular fractional shortening &lt; 22 % echocardiography exam ; Poor overall condition ECOG 34 Refusal sign inform consent Unable comply study procedure followup examination Psychiatric disorder could interfere consent , study participation followup Systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) Diagnosis another malignancy , unless patient diseasefree least 5 year follow completion curative intent therapy follow exception : Patients treat nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia , regardless diseasefree duration , eligible study definitive treatment condition complete Patients organconfined prostate cancer evidence recurrent progressive disease base prostatespecific antigen ( PSA ) value also eligible study hormonal therapy initiate radical prostatectomy perform Clinical evidence suggestive central nervous system ( CNS ) involvement leukemia unless lumbar puncture confirm absence leukemic blast cerebrospinal fluid ( CSF ) Prior positive test human immunodeficiency virus ( HIV ) History hypersensitivity study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>